© PR Newswire
10.12.2025
INNO
LISTED
CSE
Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering
News Preview
HERZLIYA, Israel and CALGARY, AB, Dec. 10, 2025 /CNW/ -- Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that, further to its press release of July 23, 2025, it has publicly filed an amendment to its registration statement on Form F-1 with the U.S. Securities and Exchange Commiss...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
MLTX
LISTED
NASDAQ
MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms
News Preview
Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025.
The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
AAWH.U
LISTED
CSE
Ascend Wellness Holdings Announces Partnership With Mister Jones in New Jersey
News Preview
Mister Jones Dispensary Set to Open December 19NEW YORK, Dec. 10, 2025 /CNW/ - Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH.U/ OTCQX:AAWH), a multi-state, vertically integrated cannabis operator, has announced a partnership agreement with Mister Jones, LLC and longtime adult-use cannabis advocate Lerone Jones. This...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
10.12.2025
AAWH.U
LISTED
CSE
Ascend Wellness Holdings Announces Partnership With Mister Jones in New Jersey
News Preview
Mister Jones Dispensary Set to Open December 19NEW YORK, Dec. 10, 2025 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH.U/ OTCQX:AAWH), a multi-state, vertically integrated cannabis operator, has announced a partnership agreement with Mister Jones, LLC and longtime adult-use cannabis advocate Lerone Jone...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
10.12.2025
CI
LISTED
NYSE
The Cigna Group Foundation Awards an Additional $3 Million in Local Grants to Support Veterans' Mental Health
News Preview
New round of funding will strengthen community-driven efforts to address housing stability by repairing and adapting homes and providing mortgage and rental assistanceBLOOMFIELD, Conn., Dec. 10, 2025 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), today announced the 2025 grant recipients for its ve...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
ANIX
LISTED
NASDAQ
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
News Preview
SAN JOSE, Calif., Dec. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Monday, D...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
AONC
LISTED
OTC
American Oncology Network Welcomes Robert J. McDonald, MD, FACNM, as Radiology Medical Director and In-House Reading Radiologist
News Preview
American Oncology Network Welcomes Robert J. McDonald, MD, FACNM, as Radiology Medical Director and In-House Reading Radiologist...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
OWLT
LISTED
NYSE
Owlet Launches Owlet360™ in the UK and Ireland, Bringing Data-Driven Reassurance to More Families
News Preview
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced the UK and Ireland launch of Owlet360™, a new subscription service designed to give parents a deeper, personalized understanding of their baby’s sleep and daily trends.
This press release features multimedia. View the full release here: htt...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
ERF
LISTED
EURONEXT
The Eurofins Consumer Product Testing Network Completes Significant Laboratory Expansion in Vietnam
News Preview
Eurofins Consumer Product Testing Vietnam has completed a major expansion, seeing the laboratory move to a purpose-built 7,000 sq. m laboratory in Ho Chi Minh City. This new facility provides more than two and a half times the floor space of Eurofins Consumer Product Testing Vietnam’s previous site. This investment strengthens the Eurofins Consume...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
OCGN
LISTED
NASDAQ
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
News Preview
MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present at the Oppenheimer Movers in Rare Disease Summit taking place at the Sofitel New Yor...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
PFE
LISTED
NYSE
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic b...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
PTCT
LISTED
NASDAQ
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
News Preview
- Broad label includes all age groups and full range of PKU subtypes -TORONTO, Dec. 10, 2025 /CNW/ - PTC Therapeutics Canada ULC announced that Health Canada has approved Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The approval includes broad labeling for the treatment of hyperphenylalaninem...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
10.12.2025
KZIA
LISTED
NASDAQ
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
News Preview
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clustersReinvigoration of immune system + turning cold tumors hotPreliminary ex-vivo data in HER2+ patients demonstrates immune reinvigoration and reductions in CTC and clustersSYDNEY, Dec. 10, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
AIMI
LISTED
OTC
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
News Preview
Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer...
Themefolio
Profiler
Peergroup
© Newsfile
10.12.2025
FEED
LISTED
NASDAQ
Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant
News Preview
Momentum continues to build for Company as series of clinical milestones are met, design choices cement differentiation from competition, and timeline comes into focusWhite Bear Lake, Minnesota--(Newsfile Corp. - December 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering full...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
SMTI
LISTED
NASDAQ
Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™
News Preview
Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic’s granted patent in 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
HCTI
LISTED
NASDAQ
Healthcare Triangle, Inc. Signs Advance Agreement for the Acquisition of Next-Generation AI Customer Engagement Business, on track to generate $34M in Revenue for FY 2025
News Preview
PLEASANTON, Calif., Dec. 10, 2025 /CNW/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announces that it has entered into an Advance Agreement with Teyame AI LLC, a St Kitts and Nevis corporation ("Teyame"), as part of its planned acquisiti...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
HCTI
LISTED
NASDAQ
Healthcare Triangle, Inc. Signs Advance Agreement for the Acquisition of Next-Generation AI Customer Engagement Business, on track to generate $34M in Revenue for FY 2025
News Preview
PLEASANTON, Calif., Dec. 10, 2025 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announces that it has entered into an Advance Agreement with Teyame AI LLC, a St Kitts and Nevis corporation ("Teyame"), as part of its planned ac...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
MBRX
LISTED
NASDAQ
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
News Preview
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
VERU
LISTED
NASDAQ
Veru to Report Fiscal Year 2025 Financial Results on December 17th
News Preview
MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discu...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
FBLG
LISTED
NASDAQ
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
News Preview
Platform Poised to Expand into Joint and Cartilage Repair Platform Poised to Expand into Joint and Cartilage Repair...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
MDMA
LISTED
CSE
PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules
News Preview
PharmAla completes delivery of a Phase 3 clinical trial contract after finishing release testing on an australian-made batch of LaNeo MDMA....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
News Preview
Lexicon Pharmaceuticals announces publication of preclinical data in the Journal of the Endocrine Society....
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
NEO
LISTED
NASDAQ
NeoGenomics to Present New ctDNA Research at SABCS 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that data utilizing its RaDaR® 1.0 assay for the detection of molecular residual disease (MRD) will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025, at the Henry B....
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
STAA
LISTED
NASDAQ
Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
News Preview
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today released the following letter to STAAR shareholders regarding the closing of STAAR’s go-shop period and the revised offer of Al...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
CTSO
LISTED
NASDAQ
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
News Preview
PRINCETON, N.J., Dec. 10, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO, will join Jason Kolbert, Head of Healthcare Research at D. B...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
STEX
LISTED
NASDAQ
Streamex Corp. (NASDAQ: STEX) Joins Solana Policy Institute in the Project Open Coalition to Advance Regulated On-Chain Trading of Real-World Assets, Including GLDY
News Preview
LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization of real-world assets, today announced it has joined Project Open, a landmark initiative working to establish a regulated framework for the issuance and trading of securities on public blockchain...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
ABSI
LISTED
NASDAQ
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
News Preview
Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
BRKR
LISTED
NASDAQ
Bruker Announces Orders for High-Performance Magnetic Resonance Systems for Materials and Life-Science Research from Leading European Institutions
News Preview
Bruker Corporation (Nasdaq: BRKR) today announced several significant European orders for high-performance magnetic resonance systems from three leading research institutions in France and Germany:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210538867/en/AVANCE NEO 1 GHz system wi...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
BEAT
LISTED
NASDAQ
HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
News Preview
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s groundbreaking 12-lead electrocardiogram (ECG) synthesis software for the assessment of arrhyt...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
PLTR
LISTED
NASDAQ
U.S. Navy Partners with Palantir to Modernize Shipbuilding Supply Chain and Accelerate Shipbuilding
News Preview
The United States Navy announced a groundbreaking partnership with Palantir Technologies Inc. (NASDAQ: PLTR) to deploy Palantir’s Foundry and Artificial Intelligence Platform (AIP) across the nation’s Maritime Industrial Base (MIB). The initiative, ShipOS, authorizes up to $448 million to accelerate the adoption of artificial intelligence and auto...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
MDNA
LISTED
TSX
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
News Preview
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case exceeding objective response rate (ORR) benchmarks in these difficult to treat populations ...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
BCT
LISTED
TSX
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, presents positive Phase 2 survival, and Phase 3 biomarker data across three...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia
News Preview
STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a clinical study of sevuparin as a potential new treatment for chronic kidney disease with anemia. The study is conducted in Italy and will evaluate the saf...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
SGMT
LISTED
NASDAQ
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
News Preview
SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a December 10 statement that China’s National Medical Products Administrati...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
News Preview
Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumor models at a medical conference in 1H 2026SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leadi...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
WST
LISTED
NYSE
West Declares Quarterly Dividend
News Preview
EXTON, Pa., Dec. 10, 2025 /PRNewswire/ -- On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on February 4, 2026, t...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
MDWD
LISTED
NASDAQ
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
News Preview
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
TLX
LISTED
ASX
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
News Preview
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix’s theranostic...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.12.2025
MAAT
LISTED
EURONEXT
First Berlin Equity Research GmbH: MaaT Pharma SACA | Rating: BUY
News Preview
Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
10.12.2025 / 11:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude c......
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
PEG
LISTED
CPH
Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S
News Preview
Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
SNWV
LISTED
NASDAQ
Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
1672
LISTED
HKSE
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
News Preview
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial.HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Asc...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
1672
LISTED
HKSE
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
News Preview
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial.HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Asc...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.12.2025
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC PINK:MDCE) Subsidiary Real Game Used Achieves Major Milestone in High-End Memorabilia Authentication
News Preview
With AI-based pattern recognition and game-used wear detection, Real Game Used is pioneering the future of authentication. MESA, ARIZONA / ACCESS Newswire / December 10, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) is proud to announce that its subsidiary, Real Game Used (RGU), has reached a significant milestone in the authentication of h...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
HIMS
LISTED
NYSE
Hims & Hers Brings Comprehensive Weight Loss Programme to the UK
News Preview
Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction of the Hers platform, helping eligible women across the UK receive access to this holistic weight management care.
This press release features multimedia. View the full...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.12.2025
JAGX
LISTED
NASDAQ
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
News Preview
Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected SAN FRANCISCO, CA / ACCESS Newswire / December 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that th...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.12.2025
IGC
LISTED
XASE
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
News Preview
POTOMAC, MD / ACCESS Newswire / December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued a coverage report e...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
RKV
LISTED
TSX
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
News Preview
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
POXEL
LISTED
EURONEXT
Poxel Publishes Its Financial Results for the First Half of 2025
News Preview
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the "Company"), announces today its condensed consolidat...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.12.2025
MODD
LISTED
NASDAQ
Modular Medical Announces Pricing of $4.68 Million Public Offering
News Preview
SAN DIEGO, CA / ACCESS Newswire / December 10, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today anno...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.12.2025
USPS
LISTED
OTC
Sannabis, Inc. (OTC: USPS) Director Meets with Colombia's Minister of Labor to Expand "Weaving Dreams of Freedom" Hemp Program for Inmates
News Preview
Sannabis plans to apply for Second Chance Opportunity Certification for these hand-crafted unique products. CALI, COLOMBIA / ACCESS Newswire / December 10, 2025 / Sannabis, Inc., f/k/a Ultimate Sports, Inc. (OTC:USPS), a U.S. Company (the "Company") planning to acquire Sannabis S.A.S ("Sannabis") in Colombia, is pleased to annou...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
IMP A-SDB
LISTED
STO
Implantica strengthens market expansion as Italy's leading Careggi University Hospital in Florence introduces RefluxStop®
News Preview
VADUZ, Liechtenstein, Dec. 10, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux (GERD), a treatment field with 1 billion sufferers, announces adoption of RefluxStop at the world-renowned Careggi U...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01
News Preview
STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has reported strong, positive results from the phase 2a clinical trial GOAL-HF1, evaluating the drug candidate AC01 in patients with heart failure and reduced ejection fraction (HFrEF). The study met its prima...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
IDIA
LISTED
SIX
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
News Preview
Allschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant Hypertension”.1 The analysis examined the efficacy and safety of aprocitentan (TRYVIO™/JERAYGO™) in patient...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
DNLI
LISTED
NASDAQ
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 sha...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
TERN
LISTED
NASDAQ
Terns Announces Pricing of Upsized $650 Million Public Offering
News Preview
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discou...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
News Preview
WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
GPCR
LISTED
NASDAQ
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
News Preview
SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary s...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
